Pharmaceutical industry is an important part of our national economy, is the combination of traditional and modern industries combined, and is an integration of first, second and tertiary industries. The main categories include: chemical raw materials and preparations, Chinese herbal medicine, Chinese herbal decoction pieces, Chinese formulated products, antibiotics, biological products, biochemical drugs, radioactive pharmaceuticals, medical equipment, sanitation materials, pharmaceutical machinery, pharmaceutical packaging and medical businesses.

Pharmaceutical industry is a high-tech industry group integrated by multi-disciplinary techniques methodologies, playing key roles in public health, social stability and economic development. Since 1978, after 30 years of reform and China's pharmaceutical industry has undergone a tremendous and rapid change. For 30 years, the growth rate of pharmaceutical industry has been higher than that of gross domestic product (GDP). From 1978 to 2007, the average annual growth of pharmaceutical industrial output is 16.8%, making it one of the fastest growing industries in the national economy.

According to the general requirements of deepening the medical and health system reform, China's pharmaceutical industry is focusing on industry restructuring, together with strengthening independent innovation, promoting new varieties and new technology R&D, and enhancing mergers and acquisitions to cultivate large enterprise groups, accelerating technological innovation, enhancing enterprise quality and international competitiveness; hence through five years of adjustments, the industry structure is going to be more rational; the development style will significant change, resulting in overall strengthened power of the industry, and the realization of gradually shifting the pharmaceutical industry from "large" to "strong".

With the emerging trend of population aging and the increasing incidence of chronic diseases, pharmaceutical market structure will also see major changes: cardiovascular, cancer and other chronic medications will replace antibiotics in use for the past 10 years, and become the largest profit growth source in the future for pharmaceutical companies. From the industry's future development trend, China's pharmaceutical industry will meet a golden decade.

The effect of new health care reform may appear in the next 3-5 years. During this time the focus of investment and emerging hot spots in the pharmaceutical industry will be the bio-pharmaceutical, herbal medicine and other "green areas", the focus of development will be the pharmaceutical distribution industry.

From January to November 2010, pharmaceutical industry realized a total income of 1.017 trillion RMB, an increase of 27.7% year on year; from January to November the export delivery value was up 22% year on year.

On October 10, 2010, " State Council's decision on accelerating the development of strategic new industries" has declared to develop biotechnology drugs, new vaccines and diagnostic reagents, chemical drugs, modern Chinese medicine and other innovative medial varieties to control major diseases; the endeavor will enhance the level of bio-pharmaceutical industry.
 

案例1：某医药企业财务咨询

项目背景

美国某跨国医药集团（世界五百强）在华业务迅速扩张，计划在中国扩大采购范围，提高采购质量，遂委托华然咨询对其采购对象做详尽的财务咨询以降低其在华采购风险。整体运营评估 /评估体系  采购商 等级  指标评价体系

华然解决方案

生产

财务

……

财务调查报告包括了基本的企业信息、股权结构、主营业务，重点分析了企业的财务状况，包括资产负债表、损益表和财务状况分析。企业财务调查报告是一类简单实用的公司调查报告，有利于客户掌握目标企业的基本信息和财务状况。

 

案例2：H医药公司投资价值研究

项目背景

某投资机构委托华然咨询对国内H非上市医药公司进行投资价值评估，作为投资依据。

华然解决方案

华然咨询的研究思路如下：

1、宏观经济环境和医药制造业分析，通过几个常用的指标对我国宏观环境和医药制造业进行分析。

2、对H医药公司分析，较为全面的对基本面和财务进行分析，价值评估，通过适当的绩效预测，采用公司自有现金流量折现法和市盈率相对法对公司的价值进行评估。

3、最后我们做出了投资风险分析与投资建议。

 

 

案例3：中药行业深度研究报告

项目背景

中药行业是赢利能力较强，产品利润率高。我国中药行业发展迅速，中成药和中药饮片的销售占国内医药市场的四成以上。某医药生产企业欲进入中药领域，委托华然咨询做中药行业研究报告作为其参考之用。

华然解决方案

中药是民族瑰宝，中药产业是我国独具特色和优势的民族产业，长期以来，世界上有近130个国家向我国进口中药原材料和成药。随着人口老龄化和疾病谱的改变，中药以其副作用小、多成分、多层次的药理作用和疗效稳定等优势，逐渐受到国际社会的重视。

2009年1-11月我国中成药制造行业实现主营业务收入169,896,388千元，比上年同期增长了22.89%；实现累计利润总额18,101,352千元，比上年同期增长了25.44%。2009年1-11月我国中药饮片加工行业实现主营业务收入43,072,160千元，比上年同期增长了25.57%；实现累计利润总额2,922,802千元，比上年同期增长了39.38%。

中药行业是国家重点扶持行业，2010年10月以来我国陆续出台了《关于建立健全基层医疗卫生机构补偿机制的意见》、《关于加快医药行业结构调整的意见》等生物医药行业支持政策。

中药材、中药饮片、中成药是中药行业的三大支柱。中药制造行业目前面临的威胁主要有落后的运行体制威胁和“洋中药”的威胁。

 

 

 

1、中药行业总体情况

2、中药行业相关扶植政策

2、中药各子行业情况

3、行业重点企业概况

4、中药行业风险

……